After completing his PhD in 2007, Ross joined AstraZeneca as a Senior Analytical Chemist in process R&D. Ross’ analytical expertise and entrepreneurial mindset was pivotal to the establishment of CatSci Ltd in 2011. Ross became CEO in 2015 and has since led the company’s pivot from a catalyst screening company to the award-winning innovation partner for medicines development that it is today. His strong company vision of CatSci becoming the leading partner for the development and manufacture of new medicines to deliver life-changing therapeutics to those in need has critically fuelled CatSci’s growth.
Ross has also recognised the promise of oligonucleotide therapeutics with RNA pipelines predicted to expand explosively in future years. However, there is still significant work to be done to de-risk both their discovery and development programs. That is why, CatSci recently launched their oligonucleotides capability dedicated to producing scalable and sustainable oligonucleotide manufacturing. Furthermore, Ross led CatSci’s partnership with Argonaute RNA and joined the company’s board as a Non-Executive Director to help drive the paradigm shift needed for the manufacturing process of oligonucleotides.
Ross has made CatSci an employee-first company that values and empowers all of the team. He has instilled a science-led and continuous improvement culture, striving for self and company innovation and evolution. His firm ‘keep learning and growing’ mantra shaped him into the entrepreneur he is today. This includes completing the Goldman Sachs-funded 10KSB programme at Saïd Business School (Oxford University) and the LSE ELITE programme.
A true entrepreneur, Ross has also launched LabLinks – a free to use digital AI powered community platform for scientists across the globe to link, learn and succeed.